Barbara Edelheit, MD

Education

Education:
BA, University of California, Berkeley, 1989
MD, SUNY-Upstate Medical University, 1996
Residency:
Pediatrics, New York-Presbyterian Hospital/Weill Cornell Medical Center, 1996-1999
Fellowship:
Rheumatology, New York-Presbyterian Hospital/Weill Cornell Medical Center, 1999-2002

Board Certifications

Faculty Appointment

Assistant Professor of Pediatrics, University of Connecticut School of Medicine

Clinical Expertise

Dr. Edelheit’s clinical interests are in autoimmune inflammatory disorders of childhood, including the Juvenile Arthritides and Juvenile Dermatomyositis. She has a special interest in Pediatric Lupus and together with Dr. Sherene Mason in the Division of Pediatric Nephrology started and co-manages our Combined Lupus clinic at Connecticut Children’s Medical Center. Dr. Edelheit volunteers with the Lupus Foundation of America and has served on the Committee for the Walk to End Lupus now for the Northeast region since 2018.

She also participates in fundraisers for the Arthritis Foundation each year and was honored by the Arthritis Foundation and asked to serve as the Medical Honoree for the 2015 Greater Hartford Walk to Cure Arthritis.

Dr. Edelheit is a member of several professional organizations including the American Medical Women’s Association (AMWA), the American College of Rheumatology (ACR), the Childhood Arthritis & Rheumatology Research Alliance (CARRA) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Selected Publications

• Li SC, Torok KS, Ishaq SS, Buckley M, Edelheit B, Ede KC, Liu C, Rabinovich CE. Preliminary Evidence on Abatacept Safety and Efficacy in Refractory Juvenile Localized Scleroderma. Rheumatology (Oxford). 2020 Dec;Keaa873. doi: 10.1093/rheumatology/keaa873. Online ahead of print.

• Mrosak J, Banasiak K, Edelheit B, Lapin C, Tory H, Collins MS. Polymyxin-B Hemoperfusion as a Novel Treatment for Rapidly Progressive Interstitial Lung Disease in a Pediatric Patient Diagnosed With Anti-MDA5 Juvenile Dermatomyositis. J Clin Rheumatol. 2019 Nov 15. doi: 10.1097/RHU.0000000000001191. [Epub ahead of print] No abstract available. PMID: 31743264

• Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA, Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, Wagner-Weiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Mehta J, Ting TV, Verbsky JW, Eberhard AB, Huang B, Giannini EH, Lovell DJ. Serum S100A8/A9 and S100A12 Levels in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 Mar;71(3):451-459. doi: 10.1002/art.40727. Epub 2019 Jan 24. PMID: 30225949

• Lovell DJ, Johnson AL, Huang B, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA, Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, WagnerWeiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Schmidt KM, Mehta J, Wahezi DM, Ting TV, Verbsky JW, Eberhard BA, Spalding S, Chen C, Giannini EH. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 Sep;70(9):1508-1518. doi: 10.1002/art.40509. Epub 2018 Jul 25. PMID: 29604189

• Stoll ML, Weiss PF, Weiss JE, Nigrovic PA, Edelheit BS, Bridges SL Jr, Danila MI, Spencer CH, Punaro MG, Schikler K, Reiff A, Kumar R, Cron RQ, Morrow CD, Lefkowitz EJ. Age and fecal microbial strainspecific differences in patients with spondyloarthritis. Arthritis Res Ther. 2018 Jan 30;20(1):14. doi: 10.1186/s13075-018-1510-6.

• Mor-Vaknin N, Rivas M, Legendre M, Mohan S, Yuanfan Y, Mau T, Johnson A, Huang B, Zhao L, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit BS, Shishov M, Jung LK, Cassidy EA, Prahalad S, Passo MH, Beukelman T, Mehta J, Giannini EH, Adams BS, Lovell DJ, Markovitz DM. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2017 Dec 29. doi: 10.1002/art.40404. [Epub ahead of print].

• Susan T. Tran, Jessica W. Guite, Ashley Pantaleao, Megan Pfeiffer, Gregory D. Myer, Soumitri Sil, Staci M. Thomas, Tracy V. Ting, Sara E. Williams, Barbara Edelheit, Sylvia Ounpuu, Jennifer Rodriguez-MacClintic, Lawrence Zemel, William Zempsky, Susmita Kashikar-ZuckPreliminary outcomes of a cross-site cognitive-behavioral and neuromuscular integrative training intervention for juvenile fibromyalgia. Arthritis Care Res (Hoboken) 2016 Jun 22. Epub 2016 Dec 22.

• Jennifer E. Weiss, Kathleen A. Haines, Elizabeth C. Chalom, Suzanne C. Li, Gary A. Walco, Themba L. Nyirenda, Barbara Edelheit and Yukiko Kimura. A randomized study of local anesthesia for pain control during intra-articular corticosteroid injection in children with arthritis. Pediatric Rheumatology 2015 13:36.3